Better, faster & safer therapeutic Ab discovery. We are changing the process with AI solutions
A French deeptech company designing and implementing computational solutions for antibodies and biodrugs discovery and development
Revolutionizes antibody discovery
MAbSilico provides a formal embedded AI-technology for antibody discovery, reducing the risks of failure and the duration of discovery and preclinical steps, as well as strengthening intellectual property protection. Conventional approaches for drug discovery take up to three years, while MAbSilico technologies allow shrinking this time to a few weeks.
Our process & method
Using AI approaches
MAbSilico’s technology is based on 20 years of academic research performed by highly competent scientists. Each methods are calibrated using parameters set up from proprietary databases during the R&D stage, and they are all validated with state-of-the-art experimental assays. Thanks to this combined approach (computational and biological), MAbSilico can show that the predictive data always converge towards the biological truth.
And a human team
The team is the best combination of computational scientists and biologists. The AI-based technologies are validated and improved in our wet-lab facility to generate a product ready for the market. The team gathers more than 100 scientific publications, and 4 patents. MAbSilico is the best combination of computational scientists and biologists.
In continuous evolution
In 2019, MAbSilico was winners of the Bpifrance “Concours d’innovation” i-Nov award. MAbSilico joined in 2020 the NVIDIA Inception program and the Microsoft Azure startup program to accelerate its development. First AI-based covid-19 peptide vaccine designed by MAbSilico reaching phase I clinical trial in 2021.
News & publications
13 therapeutics domains: 25 oncology, 12 infectiology, …
> 3M antibody characterized
40 Clients in 10 countries
1 impasse du Palais 37000 Tours